➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Express Scripts
AstraZeneca
Baxter
Dow

Last Updated: August 13, 2020

DrugPatentWatch Database Preview

Oxcarbazepine - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for oxcarbazepine and what is the scope of patent protection?

Oxcarbazepine is the generic ingredient in three branded drugs marketed by Amneal Pharms, Hikma, Sun Pharm Inds Ltd, Novartis, Supernus Pharms, Ani Pharms Inc, Breckenridge Pharm, Glenmark Pharms Ltd, Jubilant Cadista, Rubicon, Sun Pharm Inds, and Taro, and is included in fourteen NDAs. There are ten patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Oxcarbazepine has sixty patent family members in thirty-three countries.

There are twenty-one drug master file entries for oxcarbazepine. Nineteen suppliers are listed for this compound. There are two tentative approvals for this compound.

Drug Prices for oxcarbazepine

See drug prices for oxcarbazepine

Drug Sales Revenue Trends for oxcarbazepine

See drug sales revenues for oxcarbazepine

Recent Clinical Trials for oxcarbazepine

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Eisai Inc.Phase 4
Weill Medical College of Cornell UniversityPhase 4
UCB Biopharma S.P.R.L.Phase 1

See all oxcarbazepine clinical trials

Generic filers with tentative approvals for OXCARBAZEPINE
Applicant Application No. Strength Dosage Form
  Start Trial  Start Trial600MGTABLET, EXTENDED RELEASE;ORAL
  Start Trial  Start Trial300MGTABLET, EXTENDED RELEASE;ORAL
  Start Trial  Start Trial150MGTABLET, EXTENDED RELEASE;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for oxcarbazepine
Paragraph IV (Patent) Challenges for OXCARBAZEPINE
Tradename Dosage Ingredient NDA Submissiondate
OXTELLAR XR TABLET, EXTENDED RELEASE;ORAL oxcarbazepine 202810 2013-04-12
OXTELLAR XR TABLET, EXTENDED RELEASE;ORAL oxcarbazepine 202810 2013-03-20
TRILEPTAL SUSPENSION;ORAL oxcarbazepine 021285 2006-12-26
TRILEPTAL TABLET;ORAL oxcarbazepine 021014 2006-05-05

US Patents and Regulatory Information for oxcarbazepine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Taro OXCARBAZEPINE oxcarbazepine TABLET;ORAL 077801-002 Nov 15, 2007 AB RX No No   Start Trial   Start Trial   Start Trial
Glenmark Pharms Ltd OXCARBAZEPINE oxcarbazepine TABLET;ORAL 077802-001 Oct 9, 2007 AB RX No No   Start Trial   Start Trial   Start Trial
Rubicon OXCARBAZEPINE oxcarbazepine TABLET;ORAL 077747-003 Apr 9, 2008 AB RX No No   Start Trial   Start Trial   Start Trial
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-002 Oct 19, 2012 RX Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for oxcarbazepine

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis TRILEPTAL oxcarbazepine SUSPENSION;ORAL 021285-001 May 25, 2001   Start Trial   Start Trial
Novartis TRILEPTAL oxcarbazepine TABLET;ORAL 021014-002 Jan 14, 2000   Start Trial   Start Trial
Novartis TRILEPTAL oxcarbazepine TABLET;ORAL 021014-001 Jan 14, 2000   Start Trial   Start Trial
Novartis TRILEPTAL oxcarbazepine TABLET;ORAL 021014-003 Jan 14, 2000   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Harvard Business School
Moodys
McKesson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.